A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The results were published today in The New England Journal of Medicine and were first reported at the European Society for...
ABSTRACTS 93, 739, 2
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan...
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
The study, led by Kevin Nead, M.D., assistant...
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab...
ABSTRACT #7001
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed...
The American Society of Clinical Oncology (ASCO) today announced it will present three of its highest honors to faculty members from The University...
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The...